Alvogen Pine Brook LLC
General
Total Cases52
Active Cases2
Patents1
Ratings
Experience
Grade
Trend
DCT
L2
B
PTAB
L1
D
CAFC
L1
C
Analytics
Cases
Litigated Patents
Ratings Trends
Recent Dockets
Entered | Case | Description |
|---|---|---|
| 02/19/25 | Case Assigned to Judge Jennifer L. Hall. Please include the initials of the Judge (JLH) after the case number on all documents filed. (nms) (Entered: 02/19/2025) | |
| 02/18/25 | Disclosure Statement pursuant to Rule 7.1: No Parents or Affiliates Listed filed by H. Lundbeck A/S. (mpb) (Entered: 02/18/2025) | |
| 02/18/25 | Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent Otsuka Holdings Co., Ltd. for Otsuka Pharmaceutical Co., Ltd. filed by Otsuka Pharmaceutical Co., Ltd. (mpb) (Entered: 02/18/2025) | |
| 02/18/25 | Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 10,525,057; 10,980,803; 11,154,553; 11,344,547 ; 11,400,087; 11,648,347. (mpb) (Entered: 02/18/2025) | |
| 02/18/25 | Supplemental information for patent cases involving an Abbreviated New Drug Application (ANDA) - Date Patentee(s) Received Notice: 1/6/2025. Date of Expiration of Patent: September 24, 2033 and April 6, 2034.Thirty Month Stay Deadline: 7/6/2027. (mpb) (Entered: 02/18/2025) | |
| 02/18/25 | Notice, Consent and Referral forms re: U.S. Magistrate Judge jurisdiction. (mpb) (Entered: 02/18/2025) | |
| 02/18/25 | No Summons Issued. (mpb) (Entered: 02/18/2025) | |
| 02/18/25 | COMPLAINT for Patent Infringement against Almaject, Inc., Alvogen, Inc. (Filing fee $ 405, receipt number ADEDC-4615595) - filed by Otsuka Pharmaceutical Co., Ltd., H. Lundbeck A/S. (Attachments: # [1] Exhibit A, # [2] Exhibit B, # [3] Exhibit C, # [4] Exhibit D, # [5] Exhibit E, # [6] Exhibit F, # [7] Exhibit G, # [8] Exhibit H, # [9] Civil Cover Sheet)(mpb) (Entered: 02/18/2025) | |
| 12/13/24 | Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 9,132,239 B2; 10,335,462 B2; 8,129,343 B2; 8,920,383 B2; 9,457,154 B2; 9,775,953 B2. (Attachments: # [1] Stipulation of Dismissal) (mws) (Entered: 12/13/2024) | |
| 12/13/24 | SO ORDERED, re (422 in 1:22-md-03038-CFC-EGT, 36 in 1:22-cv-00297-CFC, 371 in 1:22-cv-00294-CFC-EGT) Stipulation of Dismissal Among Novo Nordisk Inc., Novo Nordisk A/S, Zydus Worldwide DMCC, Zydus Pharmaceuticals (USA) Inc., and Zydus Lifesciences, filed by Novo Nordisk A/S, Novo Nordisk Inc. (Terminating Hearings: 12/16/2024 Bench Trial terminated.) Signed by Judge Colm F. Connolly on 12/13/2024. Associated Cases: 1:22-cv-00294-CFC-EGT, 1:22-cv-00297-CFC, 1:22-md-03038-CFC-EGT(kmd) (Entered: 12/13/2024) |